Evidence for a functional β3‐adrenoceptor in man
Open Access
- 1 November 1993
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 110 (3) , 929-936
- https://doi.org/10.1111/j.1476-5381.1993.tb13902.x
Abstract
1 The existence of a functional β3-adrenoceptor in man was investigated by studying the lipolytic action of selective β-adrenoceptor agents in isolated white omental and subcutaneous fat cells. 2 The non-selective β1/β2-adrenoceptor antagonist, CGP 12177 was lipolytic in both omental and subcutaneous fat cells. The intrinsic activity relative to isoprenaline was greater in omental than in subcutaneous cells. 3 Addition of the β2-adrenoceptor antagonist, ICI 118,551 and the β1-adrenoceptor antagonist CGP20712A in combination or the non-selective β-adrenoceptor antagonist propranolol alone (all 10−7 m), induced a rightward shift of the dose-response curves for isoprenaline- and BRL37344-stimulated lipolysis of about 4 and 2 log-units, respectively. However, the antagonists did not alter lipolysis induced by CGP12177. 4 Several concentrations of β-adrenoceptor antagonists were used to determine the pA2 values by Schild analysis. The values for CGP 20712A and ICI 118,551 (6.63 ± 0.20 and 6.25 ± 0.12) as antagonists of the lipolytic effects of CGP 12177 were over 2 units lower than the pA2 value for CGP 20712A against the response to the selective β1-agonist dobutamine (8.58 ± 0.23) and the pA2 value for ICI 118,551 against the response to the selective β2-agonist terbutaline (9.15 ± 0.26). 5 β3-Adrenoceptor mRNA expression, investigated with a polymerase chain reaction assay, was demonstrated in both types of adipocytes in the same cell preparations that had a lipolytic response to CGP 12177. 6 In conclusion, human white fat cells express an atypical β-adrenoceptor in addition to β1- and β2-adrenoceptors. This receptor is stimulated more selectively by the β1-/β2-antagonist CGP 12177 than by BRL 37344 and is poorly sensitive to blockade by selective β1- and β2-antagonists. On the basis of the pharmacological properties and the mRNA analyses, we suggest that this atypical receptor corresponds to the β3-adrenoceptor subtype.Keywords
This publication has 28 references indexed in Scilit:
- Lipolytic catecholamine resistance due to decreased beta 2-adrenoceptor expression in fat cells.Journal of Clinical Investigation, 1992
- Importance of beta‐adrenoceptor function in fat cells for lipid mobilizationEuropean Journal of Clinical Investigation, 1992
- Differential adrenergic regulation of beta 1- and beta 3-adrenoreceptor messenger ribonucleic acids in adipose tissuesEndocrinology, 1992
- Discrepancies in Lipolytic Activities Induced by β-Adrenoceptor Agonists in Human and Rat AdipocytesHormone and Metabolic Research, 1990
- Is the adipocyte β-adrenoceptor a prototype for the recently cloned atypical ‘β3-adrenoceptor?’Trends in Pharmacological Sciences, 1990
- How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated?Journal of Pharmacy and Pharmacology, 1978
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973
- Differentiation of Receptor Systems activated by Sympathomimetic AminesNature, 1967
- The effect of insulin on the metabolism of human adipose tissue in vitroBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1965
- FATTY-ACID METABOLISM BY HUMAN ADIPOSE TISSUES*Journal of Clinical Investigation, 1963